Aadi Bioscience (AADI)
(Delayed Data from NSDQ)
$1.91 USD
-0.02 (-1.04%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $1.91 0.00 (0.00%) 4:30 PM ET
2-Buy of 5 2
D Value C Growth F Momentum D VGM
Brokerage Reports
0 items in cart
Aadi Bioscience, Inc. [AADI]
Reports for Purchase
Showing records 1 - 19 ( 19 total )
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
PRECISION1 Trial Discontinued; 2Q24 Financials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
PRECISION-1 Response Rate Worse Than Expected; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Interim PRECISION 1 Data Imminent; 3Q23 Financials; Lowering PT to $36
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
PRECISION 1 Data Remains in Focus; 2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Updates from ASCO; Near-Term Focus Remains on PRECISION 1; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
PRECISION 1 Results Expected by Year-End; 1Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
PRECISION 1 Trial Data in 2Q23; 4Q22 Financials; Modulating PT to $45
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Collaboration Inked With Mirati; Preclinical Data Supports KRAS Combo; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
PRECISION 1 Interim Results in 1H23; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Continued FYARRO Impact in TSC1 and TSC2 Alterations; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
NGS Partnerships Inked; FYARRO Sales Beat Consensus; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
PRECISION 1 Trial Dosing Starts; 2021 Financials; Adjusting PT to $48
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
As Expected, the FDA Greenlights FYARRO for PEComa; Raising PT to $49
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
FYARRO Approval Decision Imminent; 3Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Reverse Merger Completed; 2Q21 Financial Results; Raising PT to $47
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
|